Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
NCT02479308Phase 1Completed
- Sponsor
- Alkermes
- Start
- Jun 2015
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of buprenorphine + samidorphan in major depressive disorder (MDD) (3 arms), sponsored by Alkermes. Primary endpoint: Change in QT interval corrected for heart rate using the Fridericia formula up to 14 days. Started Jun 2015; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02479308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02479308.